Edgewise Therapeutics, Inc., a biopharmaceutical company, is developing small molecule therapies for musculoskeletal diseases. The company's product candidates target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics was incorporated in 2017 and is headquartered in Boulder, CO.
Name / Ticker | Price | Zen Rating |
---|---|---|
$133.96 | A | |
$21.57 | A | |
$5.87 | A |